Related Experiment Video
Updated: Aug 3, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
[Cerebral infarction and transient ischemic attack]
Insights
The 2015 Japanese Stroke Guidelines expand treatment windows for cerebral infarction and transient ischemic attack (TIA). Key updates include extended thrombolysis times and new recommendations for antiplatelet and anticoagulant therapies.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Public Health
Context:
- The 2015 Japanese Guidelines for the Management of Stroke provide updated recommendations for clinical practice.
- Cerebral infarction and transient ischemic attack (TIA) management have seen significant revisions since the 2009 edition.
- These guidelines are crucial for healthcare professionals managing stroke patients in Japan.
Purpose:
- To outline the key revisions in the 2015 Japanese Guidelines concerning cerebral infarction and TIA.
- To inform clinicians about updated treatment protocols and therapeutic options.
- To enhance the quality of stroke care through evidence-based recommendations.
Summary:
- The 2015 guidelines extend the time window for intravenous recombinant tissue-plasminogen activator treatment to within 4.5 hours.
- Dual antiplatelet therapy (DAPT) is recommended for acute non-cardioembolic ischemic stroke or TIA.
- New recommendations include endovascular recanalization therapy, chronic stage antiplatelet therapy with cilostazol, and the use of Non-vitamin K antagonist oral anticoagulants (NOACs) for NVAF patients.
Impact:
- These revisions aim to improve patient outcomes by optimizing acute treatment strategies.
- The updated guidelines facilitate more effective secondary prevention through revised antiplatelet and anticoagulant recommendations.
- Standardizing TIA management is expected to reduce the risk of subsequent strokes.
Abstract:
Japanese Guidelines for the Management of Stroke 2015 was published. Here, we describe several points revised from the 2009 edition about "Cerebral infarction and transient ischemic attack (TIA)". The revision points are as follows; 1. Extension of possible time window of intravenous recombinant tissue-plasminogen activator treatment (from within 3 hours to within 4.5 hours); 2. Antiplatelet therapy in acute stage (dual antiplatelet therapy (DAPT) for non-cardioembolic ischemic stroke or TIA); 3. Endovascular recanalization therapy in acute stage; 4. Antiplatelet therapy in chronic stage (Cilostazol is recommended similar to aspirin or clopidogrel); 5. Non-vitamin K antagonist oral anticoagulants (NOACs) for non-valvular atrial fibrillation (NVAF) stroke or TIA patients; 6. Management of TIA. We explain the revised points of the guideline in the text.
Related Concept Videos
Stroke: Introduction and Types
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Transient Ischemic Attack l: Introduction

